Mirtazapin Ratiopharm (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Ratiopharm, is a noradrenergic and specific serotonergic antidepressant (NaSSA) presented as an oral tablet for systemic use. It is prescribed for the treatment of major depressive disorder in adult patients, helping to alleviate depressive symptoms by modulating neurotransmitter activity.

GNH USA supplies Mirtazapin Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with the product sourced from the European Union market.

Mirtazapine acts on neurotransmitter pathways involved in mood regulation and is indicated for several depressive conditions. - Major depressive disorder: reduces depressive symptoms and improves mood in adult patients. - Depressive episodes in bipolar disorder: may be used as an adjunct to stabilize mood when depressive phases predominate. - Treatment‑resistant depression: can be considered when first‑line antidepressants have not achieved adequate response.

Mirtazapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Sedation or somnolence. - Increased appetite leading to weight gain. - Dry mouth. - Constipation.

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia. - Anaphylactic or severe allergic reactions. - Emergence or worsening of suicidal thoughts, particularly early in therapy.

Before initiating therapy, clinicians should consider several safety aspects. - Assess hepatic function: adjust dosing in severe impairment. - Monitor weight: watch for significant gain during treatment. - Evaluate for suicidal ideation: especially at treatment start. - Caution in elderly: increased fall risk due to sedation. - Avoid abrupt discontinuation: taper under medical supervision. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Mirtazapine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Strong CYP2D6 inhibitors (e.g., fluoxetine): may raise mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - Central nervous system depressants (e.g., benzodiazepines, alcohol): additive sedation. - Anticholinergic agents: increased anticholinergic burden. - Other serotonergic drugs (e.g., SSRIs, SNRIs): potential for serotonin syndrome.